Stay updated on PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T16:07:27.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Removed the government funding lapse notice and Revision: v3.4.1 banner.
    Difference
    0.4%
    Check dated 2026-02-11T02:35:57.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a banner about government funding status and updated the page revision to v3.4.1, replacing the previous v3.4.0 revision note.
    Difference
    0.4%
    Check dated 2026-02-03T23:35:12.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page now includes a glossary control and updates several footer/metadata items, including Last Update Submitted that Met QC Criteria, Last Update Posted, capitalization changes to No FEAR Act Data, and the revision noted as v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-27T23:55:14.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3.
    Difference
    0.0%
    Check dated 2026-01-14T01:35:24.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The page now includes a dedicated Locations section identifying Maryland (Baltimore, MD) as the study site, clarifying where the trial is conducted. It also shows the removal of the HHS Vulnerability Disclosure link and the prior Maryland Locations entry, with the revision updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T08:44:42.000Z thumbnail image

Stay in the know with updates to PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.